clinical trial · NCT04771130
A Study of BGB-11417 in Participants With Myeloid Malignancies
BeiGene·phase2·recruiting·n = 260
Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmBGB-11417AzacitidinePosaconazoleBGB-11417BGB-11417
brief summary
The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .
started
May 24, 2021
primary completion
Feb 8, 2028
completion
Feb 8, 2028
last updated
Apr 23, 2026
official title
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol